Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

1. Linezolid versus vancomycin for skin and soft tissue infections.The Cochrane database of systematic reviews · 2016
   Pooled it
2. Staphylococcal infections and infertility: mechanisms and management.Molecular and cellular biochemistry · 2020
   Review
3. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2010
   Article
4. Current and novel antibiotics against resistant Gram-positive bacteria.Infection and drug resistance · 2008
   Article

Corrections and comments

• Comment on
  Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.2005

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as